A Landmark Scientific Moment
In what is being called a landmark moment for cancer treatment, a therapy designed specifically for each patient has shown it can significantly prevent the return of melanoma, the most dangerous form of skin cancer. The treatment, developed by Moderna
and Merck, is an individualised neoantigen therapy known as intismeran (or V940/mRNA-4157). The recently announced results come from a Phase 3 clinical trial—the final and most crucial stage of testing before seeking regulatory approval. This is the first time any personalised mRNA cancer therapy has passed this critical milestone, showing a clear benefit when added to a standard-of-care immunotherapy drug, Keytruda. The combination was more effective at preventing cancer recurrence and its spread to other parts of the body compared to using Keytruda alone.
How Does a Personalised Vaccine Work?
Unlike traditional vaccines that prevent infectious diseases, this cancer vaccine is a therapeutic treatment. It's not designed to stop you from getting cancer, but to train your immune system to fight the cancer that's already there and prevent it from coming back. The process is highly personalised. First, doctors take a sample of a patient's surgically removed tumour and compare its genetic sequence to that of their healthy cells. This comparison identifies unique mutations present only in the cancer cells. These mutations cause the cancer cells to produce unique proteins on their surface called neoantigens. Using the same mRNA technology behind many COVID-19 vaccines, scientists create a bespoke vaccine for each patient. This vaccine contains mRNA instructions for up to 34 of the patient's specific neoantigens. When injected, the vaccine teaches the patient's immune system to recognise these neoantigens as foreign and hunt down any cancer cells that carry them.
The Importance of Phase 3 and The Results
A Phase 3 trial is a massive undertaking, designed to confirm a treatment's effectiveness and safety in a large, diverse group of people. The INTerpath-001 trial enrolled 1,137 patients with high-risk melanoma whose tumours had been completely removed by surgery. The trial directly compared patients receiving just the immunotherapy drug Keytruda against those receiving Keytruda plus the personalised vaccine. The companies announced the study met its primary goals: significantly improving recurrence-free survival (how long a patient lives without their cancer returning) and distant metastasis-free survival (how long a patient lives without the cancer spreading). While detailed numbers have not yet been released, the companies described the improvements as both "statistically significant and clinically meaningful." The positive results build on earlier Phase 2 data which showed the combination reduced the risk of recurrence or death by 49% over a five-year period. Safety was also consistent with previous studies, with no new concerning signals identified.
The Road Ahead for Cancer Vaccines
This success in melanoma is seen by many scientists as a proof of concept for a new class of cancer treatments. It establishes personalised vaccines as a viable and powerful addition to the cancer-fighting arsenal. The next steps involve sharing the full data with regulatory bodies like the US Food and Drug Administration to seek approval for widespread use in melanoma patients. However, challenges remain. Creating a unique vaccine for every single patient is a complex and time-consuming process. The cost and scalability of such a personalised manufacturing process will be significant hurdles to overcome. Despite this, the potential is enormous. Trials are already underway to test this personalised vaccine approach in other cancers, including lung, bladder, and kidney cancer, offering hope that this breakthrough could one day benefit a much wider group of patients.
